Any feedback?
Please rate this page
(enzyme.php)
(0/150)

BRENDA support

Disease on EC 1.14.11.68 - [histone H3]-trimethyl-L-lysine27 demethylase

Please use the Disease Search for a specific query.
Please wait a moment until all data is loaded. This message will disappear when all data is loaded.
DISEASE
TITLE OF PUBLICATION
LINK TO PUBMED
Acrocephalosyndactylia
Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome.
Adenocarcinoma
Blocking the road to de-differentiation: HNF1A/KDM6A complex safeguards epithelial integrity in pancreatic cancer.
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
Alagille Syndrome
Cystic biliary atresia with paucity of bile ducts and gene mutation in KDM6A: a case report.
Amyloidosis
A highly heterogeneous mutational pattern in POEMS syndrome.
Apnea
A novel mouse model of obstructive sleep apnea by bulking agent-induced tongue enlargement results in left ventricular contractile dysfunction.
Arthritis
LncRNA H19 regulates macrophage polarization and promotes Freund's complete adjuvant-induced arthritis by upregulating KDM6A.
Autoimmune Diseases
Demethylase Kdm6a epigenetically promotes IL-6 and IFN-? production in macrophages.
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Biliary Atresia
Cystic biliary atresia with paucity of bile ducts and gene mutation in KDM6A: a case report.
Breast Neoplasms
Characterization of Nigerian breast cancer reveals prevalent homologous recombination deficiency and aggressive molecular features.
Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
Inhibition of Histone Demethylases LSD1 and UTX Regulates ER? Signaling in Breast Cancer.
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
Carcinogenesis
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
The mutational landscape of adenoid cystic carcinoma.
Carcinoma
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Epigenetic modifiers: activities in renal cell carcinoma.
Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma.
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress.
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
System Review about Function Role of ESCC Driver Gene KDM6A by Network Biology Approach.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Carcinoma, Adenoid Cystic
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
Carcinoma, Hepatocellular
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Carcinoma, Renal Cell
Clinical and pathological impact of VHL, PBRM1, BAP1, SETD2, KDM6A, and JARID1c in clear cell renal cell carcinoma.
Epigenetic modifiers: activities in renal cell carcinoma.
Loss of chromosome Y leads to down regulation of KDM5D and KDM6C epigenetic modifiers in clear cell renal cell carcinoma.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Carcinoma, Squamous Cell
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
Chordoma
Inhibition of histone H3K27 demethylases inactivates brachyury (TBXT) and promotes chordoma cell death.
Cleft Palate
Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate.
Coloboma
A case of exudative vitreoretinopathy and chorioretinal coloboma associated with microcephaly in a female with contiguous Xp11.3-11.4 deletion.
Colonic Neoplasms
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Colorectal Neoplasms
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Congenital Abnormalities
Tooth agenesis and orofacial clefting: genetic brothers in arms?
Congenital Hyperinsulinism
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Congenital, Hereditary, and Neonatal Diseases and Abnormalities
Identification of KMT2D and KDM6A variants by targeted sequencing from patients with Kabuki syndrome and other congenital disorders.
Craniosynostoses
Pharmacological targeting of KDM6A and KDM6B, as a novel therapeutic strategy for treating craniosynostosis in Saethre-Chotzen syndrome.
Diabetic Nephropathies
A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction.
hsa-miR-199b-3p Prevents the Epithelial-Mesenchymal Transition and Dysfunction of the Renal Tubule by Regulating E-cadherin through Targeting KDM6A in Diabetic Nephropathy.
Encephalomyelitis
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
X-tra X: An escape to autoimmunity.
Encephalomyelitis, Autoimmune, Experimental
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
X-tra X: An escape to autoimmunity.
Esophageal Squamous Cell Carcinoma
System Review about Function Role of ESCC Driver Gene KDM6A by Network Biology Approach.
Gastrointestinal Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Genetic Diseases, Inborn
Changes in ocular motility in Kabuki syndrome.
Ophthalmic manifestations in Kabuki (make-up) syndrome: A single-center pediatric cohort and systematic review of the literature.
Graft vs Host Disease
Genetic Profile and Microsatellite Instability in a Case of Secondary Esophageal Squamous Cell Carcinoma 12 Years After Allogeneic Hematopoietic Stem Cell Transplantation for Aplastic Anemia.
Hearing Loss, Sensorineural
Clinical update on sensorineural hearing loss in Turner syndrome and the X-chromosome.
Hydrocephalus
Novel KDM6A splice-site mutation in kabuki syndrome with congenital hydrocephalus: a case report.
Hyperinsulinism
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Hypertrichosis
Novel KDM6A (UTX) mutations and a clinical and molecular review of the X-linked Kabuki syndrome (KS2).
Hypoglycemia
A Rare Cause of Hyperinsulinemic Hypoglycemia: Kabuki Syndrome
Hypogonadism
Peripheral Precocious Puberty of Ovarian Origin in a Series of 18 Girls: Exome Study Finds Variants in Genes Responsible for Hypogonadotropic Hypogonadism.
Infections
[Treatment and genetic analysis of a child with Kabuki syndrome type 2 and secondary pulmonary infection due to a de novo variant of KDM6A gene].
Influenza, Human
Long-term exposure to PM2.5 lowers influenza virus resistance via down-regulating pulmonary macrophage Kdm6a and mediates histones modification in IL-6 and IFN-? promoter regions.
Intellectual Disability
Kabuki Syndrome-Clinical Review with Molecular Aspects.
Kabuki syndrome: international consensus diagnostic criteria.
Klinefelter Syndrome
Epigenetics and genomics in Turner syndrome.
Leukemia
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
Leukemia, Myeloid, Acute
Gene expression changes contribute to stemness and therapy resistance of relapsed acute myeloid leukemia: roles of SOCS2, CALCRL, MTSS1, and KDM6A.
Loss of KDM6A confers drug resistance in acute myeloid leukemia.
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Leukemia, Myelomonocytic, Chronic
Multilayer intraclonal heterogeneity in chronic myelomonocytic leukemia.
Leukemia, T-Cell
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Liver Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Lung Neoplasms
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
Lymphoma
Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Medulloblastoma
Novel mutations target distinct subgroups of medulloblastoma.
OTX2 sustains a bivalent-like state of OTX2-bound promoters in medulloblastoma by maintaining their H3K27me3 levels.
Melanoma
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Mesothelioma
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
Mesothelioma, Malignant
Kdm6a and Kdm6b: Altered expression in malignant pleural mesothelioma.
Metabolic Syndrome
Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity.
Microcephaly
A case of exudative vitreoretinopathy and chorioretinal coloboma associated with microcephaly in a female with contiguous Xp11.3-11.4 deletion.
Multiple Myeloma
A highly heterogeneous mutational pattern in POEMS syndrome.
Muscle Hypotonia
Kabuki Syndrome-Clinical Review with Molecular Aspects.
Kabuki syndrome: international consensus diagnostic criteria.
MLL2 and KDM6A mutations in patients with Kabuki syndrome.
Neoplasm Metastasis
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Molecular alterations associated with metastases of solid pseudopapillary neoplasms of the pancreas.
Neoplasms
A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.
A Diffusion-like Process Accommodates New Crypts During Clonal Expansion in Human Colonic Epithelium.
Aberrant patterns of H3K4 and H3K27 histone lysine methylation occur across subgroups in medulloblastoma.
Aberrant promoter hypermethylation of PBRM1, BAP1, SETD2, KDM6A and other chromatin-modifying genes is absent or rare in clear cell RCC.
Cancer Management in Kabuki Syndrome: The First Case of Wilms Tumor and a Literature Review.
Chemotherapy-induced S100A10 recruits KDM6A to facilitate OCT4-mediated breast cancer stemness.
Chromosomal abnormalities and molecular landscape of metastasizing mucinous salivary adenocarcinoma.
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Combined inhibition of heat shock proteins 90 and 70 leads to simultaneous degradation of the oncogenic signaling proteins involved in muscle invasive bladder cancer.
Comprehensive genomic profiling of small cell lung cancer in Chinese patients and the implications for therapeutic potential.
Comprehensive integrative profiling of upper tract urothelial carcinomas.
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
dbEM: A database of epigenetic modifiers curated from cancerous and normal genomes.
Dissecting the genomic complexity underlying medulloblastoma.
Distinct genomic subclasses of high-grade/progressive meningiomas: NF2-associated, NF2-exclusive, and NF2-agnostic.
Driver mutations of cancer epigenomes.
Enzyme kinetic studies of histone demethylases KDM4C and KDM6A: towards understanding selectivity of inhibitors targeting oncogenic histone demethylases.
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Epigenetic modifiers: activities in renal cell carcinoma.
Epigenetic regulation in RCC: opportunities for therapeutic intervention?
Epigenetic regulation of epithelial-mesenchymal transition by KDM6A histone demethylase in lung cancer cells.
Epstein-Barr virus-negative extranodal "true" natural killer-cell lymphoma harbouring a KDM6A mutation.
Expression of the epigenetic H3K27me3 modifier genes KDM6A and EZH2 in patients with upper tract urothelial carcinoma.
Genetic Alterations in the Molecular Subtypes of Bladder Cancer: Illustration in the Cancer Genome Atlas Dataset.
Genetic profiling of patients with adenoid cystic carcinoma of the Bartholin's glands reveals potential new routes for targeted therapies: a case report.
Genomic analyses identify molecular subtypes of pancreatic cancer.
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Genomic Profiling Identified ERCC2 E606Q Mutation in Helicase Domain Respond to Platinum-Based Neoadjuvant Therapy in Urothelial Bladder Cancer.
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Histone 3 lysine-27 demethylase KDM6A coordinates with KMT2B to play an oncogenic role in NSCLC by regulating H3K4me3.
Histone demethylase KDM6B inhibits breast cancer metastasis by regulating Wnt/?-catenin signaling.
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
Human papillomavirus dysregulates the cellular apparatus controlling the methylation status of H3K27 in different human cancers to consistently alter gene expression regardless of tissue of origin.
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Intergenerational epigenetic inheritance of cancer susceptibility in mammals.
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
KDM6A promotes imatinib resistance through YY1-mediated transcriptional upregulation of TRKA independently of its demethylase activity in chronic myelogenous leukemia.
KDM6A suppresses hepatocellular carcinoma cell proliferation by negatively regulating the TGF-?/SMAD signaling pathway.
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Knockdown of UTX/KDM6A Enriches Precursor Cell Populations in Urothelial Cell Cultures and Cell Lines.
Local sequence assembly reveals a high-resolution profile of somatic structural variations in 97 cancer genomes.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Loss of KDM6A confers drug resistance in acute myeloid leukemia.
Loss of PBRM1 expression is associated with renal cell carcinoma progression.
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Lysine Demethylase KDM6A in Differentiation, Development, and Cancer.
Lysine demethylases KDM6A and UTY: The X and Y of histone demethylation.
MBD3/NuRD loss participates with KDM6A program to promote DOCK5/8 expression and Rac GTPase activation in human acute myeloid leukemia.
Molecular alterations and targeted therapy in pancreatic ductal adenocarcinoma.
Molecular correlates and therapeutic targets in T cell-inflamed versus non-T cell-inflamed tumors across cancer types.
Molecular Landscape of Non-Muscle Invasive Bladder Cancer.
Mutational analysis of 472 urothelial carcinoma across grades and anatomic sites.
Novel molecular targets in gastric adenocarcinoma.
Novel mutations target distinct subgroups of medulloblastoma.
Puerarin 6?-O-xyloside suppressed HCC via regulating proliferation, stemness, and apoptosis with inhibited PI3K/AKT/mTOR.
Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
Resetting the epigenetic balance of Polycomb and COMPASS function at enhancers for cancer therapy.
Significance of KDM6A mutation in bladder cancer immune escape.
Sleeping Beauty mutagenesis reveals cooperating mutations and pathways in pancreatic adenocarcinoma.
Somatic mutations altering EZH2 (Tyr641) in follicular and diffuse large B-cell lymphomas of germinal-center origin.
Study of the Female Sex Survival Advantage in Melanoma-A Focus on X-Linked Epigenetic Regulators and Immune Responses in Two Cohorts.
Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
TET2 binds the androgen receptor and loss is associated with prostate cancer.
The cancer driver genes IDH1/2, JARID1C/ KDM5C, and UTX/ KDM6A: crosstalk between histone demethylation and hypoxic reprogramming in cancer metabolism.
The evolution of bladder cancer genomics: What have we learned and how can we use it?
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
The histone demethylase UTX/KDM6A in cancer: Progress and puzzles.
Transposon mutagenesis identifies genes and cellular processes driving epithelial-mesenchymal transition in hepatocellular carcinoma.
UTX-mediated enhancer and chromatin remodeling suppresses myeloid leukemogenesis through noncatalytic inverse regulation of ETS and GATA programs.
X chromosome protects against bladder cancer in females via a KDM6A-dependent epigenetic mechanism.
[KDM6A mutation and expression in gastric cancer are associated with prognosis].
Neuroinflammatory Diseases
The X-linked histone demethylase Kdm6a in CD4+ T lymphocytes modulates autoimmunity.
Obesity
Kdm6a suppresses the alternative activation of macrophages and impairs energy expenditure in obesity.
Restoration of H3k27me3 Modification Epigenetically Silences Cry1 Expression and Sensitizes Leptin Signaling to Reduce Obesity-Related Properties.
Osteoarthritis
KDM6A promotes chondrogenic differentiation of periodontal ligament stem cells by demethylation of SOX9.
The therapeutic effect of bone marrow-derived mesenchymal stem cells on osteoarthritis is improved by the activation of the KDM6A/SOX9 signaling pathway caused by exposure to hypoxia.
Pancreatic Neoplasms
Histone H3K27 demethylase KDM6A is an epigenetic gatekeeper of mTORC1 signalling in cancer.
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
KDM6A Loss Induces Aggressive Pancreatic Cancer in Mice.
Loss of KDM6A Activates Super-Enhancers to Induce Gender-Specific Squamous-like Pancreatic Cancer and Confers Sensitivity to BET Inhibitors.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.
Precursor T-Cell Lymphoblastic Leukemia-Lymphoma
Deleterious point mutations in T-cell acute lymphoblastic leukemia: Mechanistic insights into leukemogenesis.
Genomic characterization of pediatric T-cell acute lymphoblastic leukemia reveals novel recurrent driver mutations.
Proteinuria
A KDM6A-KLF10 reinforcing feedback mechanism aggravates diabetic podocyte dysfunction.
Pulmonary Disease, Chronic Obstructive
Combination of lysine-specific demethylase 6A (KDM6A) and mismatch repair (MMR) status is a potential prognostic factor in colorectal cancer.
Seizures
Haploinsufficiency of KDM6A is associated with severe psychomotor retardation, global growth restriction, seizures and cleft palate.
Sepsis
KDM6A Lysine Demethylase Directs Epigenetic Polarity of MDSCs during Murine Sepsis.
Spinal Cord Injuries
MicroRNA-145-Mediated KDM6A Downregulation Enhances Neural Repair after Spinal Cord Injury via the NOTCH2/Abcb1a Axis.
Squamous Cell Carcinoma of Head and Neck
The head and neck cancer cell oncogenome: a platform for the development of precision molecular therapies.
Stomach Neoplasms
Expression pattern of histone lysine-specific demethylase 6B in gastric cancer.
Synergistic triad epistasis of epigenetic H3K27me modifier genes, EZH2, KDM6A, and KDM6B, in gastric cancer susceptibility.
[KDM6A mutation and expression in gastric cancer are associated with prognosis].
Stroke
X chromosome escapee genes are involved in ischemic sexual dimorphism through epigenetic modification of inflammatory signals.
Tics
Targeted inhibition of KDM6 histone demethylases eradicates tumor-initiating cells via enhancer reprogramming in colorectal cancer.
Triple Negative Breast Neoplasms
Genetic events in the progression of adenoid cystic carcinoma of the breast to high-grade triple-negative breast cancer.
The H3K27me3-demethylase KDM6A is suppressed in breast cancer stem-like cells, and enables the resolution of bivalency during the mesenchymal-epithelial transition.
Turner Syndrome
Congenital Hyperinsulinism in Infants with Turner Syndrome: Possible Association with Monosomy X and KDM6A Haploinsufficiency.
Mutation Update for Kabuki Syndrome Genes KMT2D and KDM6A and Further Delineation of X-Linked Kabuki Syndrome Subtype 2.
Urinary Bladder Neoplasms
A cell of origin gene signature indicates human bladder cancer has distinct cellular progenitors.
Concurrent alterations in TERT, KDM6A, and the BRCA pathway in bladder cancer.
EP300 mutation is associated with tumor mutation burden and promotes antitumor immunity in bladder cancer patients.
Genomic Subtypes of Non-invasive Bladder Cancer with Distinct Metabolic Profile and Female Gender Bias in KDM6A Mutation Frequency.
Inhibition of EZH2 induces NK cell-mediated differentiation and death in muscle-invasive bladder cancer.
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Loss of tumor suppressor KDM6A amplifies PRC2-regulated transcriptional repression in bladder cancer and can be targeted through inhibition of EZH2.
Multiplex PCR and Next Generation Sequencing for the Non-Invasive Detection of Bladder Cancer.
Re: Loss of Tumor Suppressor KDM6A Amplifies PRC2-Regulated Transcriptional Repression in Bladder Cancer and Can be Targeted through Inhibition of EZH2.
Significance of KDM6A mutation in bladder cancer immune escape.
Uterine Cervical Neoplasms
KDM6A addiction of cervical carcinoma cell lines is triggered by E7 and mediated by p21CIP1 suppression of replication stress.
[histone h3]-trimethyl-l-lysine27 demethylase deficiency
HNF1A recruits KDM6A to activate differentiated acinar cell programs that suppress pancreatic cancer.
Kdm6a Deficiency Activates Inflammatory Pathways, Promotes M2 Macrophage Polarization, and Causes Bladder Cancer in Cooperation with p53 Dysfunction.
KDM6A-ARHGDIB axis blocks metastasis of bladder cancer by inhibiting Rac1.
Loss of KDM6A characterizes a poor prognostic subtype of human pancreatic cancer and potentiates HDAC inhibitor lethality.